Table 1 Demographic and clinical characteristics of patients received dentoalveolar surgery (n = 97)
From: Clinical values of serum Semaphorin 4D (Sema4D) in medication‑related osteonecrosis of the jaw
Characteristics | Study group | p | |
|---|---|---|---|
Non-MRONJ (n = 55) | MRONJ (n = 42) | ||
Gender | |||
Male | 21 (38.2%) | 14 (33.3%) | 0.674 |
Female | 34 (61.8%) | 28 (66.7%) | |
Age (years) | 65.4 ± 9.6 | 68.7 ± 10.7 | 0.108 |
Duration of bisphosphonate exposure (months) | 44.2 ± 27.8 | 51.1 ± 32.5 | 0.223 |
Indication for bisphosphonate treatment | |||
Osteoporosis | 36 (65.5%) | 30 (71.4%) | 0.661 |
Bone metastasis | 19 (34.5%) | 12 (28.6%) | |
Administration route | |||
IV | 20 (36.4%) | 22 (52.4%) | 0.149 |
PO | 35 (63.6%) | 20 (47.6%) | |
Bisphosphonates use | |||
Alendronate | 12 (21.8%) | 8 (19%) | 0.212 |
Pamidronate | 3 (5.5%) | 1 (2.4%) | |
Ibandronate | 16 (29.1%) | 16 (38.1%) | |
Zoledronate | 22 (40%) | 11 (26.2%) | |
Risedronate | 2 (3.6%) | 6 (14.3%) | |
Dentoalveolar surgery | |||
Tooth extraction | 36 (65.5%) | 25 (59.5%) | 0.765 |
Dental prosthesis | 11 (20%) | 11 (26.2%) | |
Root cannel procedure | 8 (14.5%) | 6 (14.3%) | |
Location | |||
Mandible | – | 28 (66.7%) | – |
Maxilla | 11 (26.2%) | ||
Mandible and maxilla | 3 (7.1%) | ||
Stage | |||
I | – | 15 (35.7%) | – |
II | 19 (45.2%) | ||
III | 8 (19.1%) | ||